Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Lack of Significance of the BRCA2 Promoter Methylation Status in Different Genotypes of the MTHFR a1298c Polymorphism in Ovarian Cancer Cases in Iran

  • Published : 2012.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Promoter methylation, which can be regulated by MTHFR activity, is associated with silencing of genes. In this study we evaluated the methylation status (type) of the BRCA2 promoter in ovarian cancer patients carrying different genotypes of the MTHFR gene (A or C polymorphisms at position 1298). Methods: The methylation type of the BRCA2 promoter was evaluated using bisulfate-modified DNA in methylation-specific PCR and the MTHFRa1278c polymorphism was assessed by PCR-RFLP. Results: Analysis of the BRCA2 promoter methylation type of cases showed that 7 out of 60 cases (11.7%) were methylated while the remaining 53 (88.3%) were unmethylated. In methylated cases, one out of the 7 cases had a CC genotype and the remaining 6 methylated cases had an AC genotype. The AA genotype was absent. In unmethylated cases, 34, 18, and one out of these had AC, AA and CC genotype, respectively. Conclusion: There was no significant relationship between the methylation types of the BRCA2 promoter in different genotypes of MTHFRa1298c polymorphism in ovarian cancer; p=0.255. There was no significant relation between the methylation types of the BRCA2 promoter in different genotypes of the MTHFRa1298c polymorphism in ovarian cancer.

Keywords

References

  1. Asadollahi R, Hyde CA, Zhong XY (2010). Epigenetics of ovarian cancer: from the lab to the clinic. Gynecol Oncol, 118, 81-7. https://doi.org/10.1016/j.ygyno.2010.03.015
  2. An J, Wei Q, Liu Z, et al (2010). Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis. Int J Mol Epidemiol Genet, 1, 1-10.
  3. Costello JF, Frühwald MC, Smiraglia DJ, et al (2000). Aberrant CpG-island methylation has nonrandom and tumour-typespecific patterns. Nat Genet, 24, 132-8. https://doi.org/10.1038/72785
  4. Esteller M, Corn PG, Baylin SB, Herman JG (2001). A gene hypermethylation profile of human cancer. Cancer Re, 61, 3225-9.
  5. Hilton JL, Geisler JP, Rathe JA, et al (2002). Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst, 94, 1396-400. https://doi.org/10.1093/jnci/94.18.1396
  6. Holschneider CH, Berek JS (2000). Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol, 19, 3-10. https://doi.org/10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S
  7. Gudmundsdottir K, Ashworth A (2006). The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene, 25, 5864-74. https://doi.org/10.1038/sj.onc.1209874
  8. Jakubowska A, Gronwald J, Menkiszak J, et al (2007). Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Breast Cancer Res Treat, 104, 299-308. https://doi.org/10.1007/s10549-006-9417-3
  9. Kanai Y, Hirohashi S (2007). Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis, 28, 2434-42. https://doi.org/10.1093/carcin/bgm206
  10. Lin J, Spitz MR, Wang Y, et al (2004). Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a casecontrol study. Carcinogenesis, 25, 1639-47. https://doi.org/10.1093/carcin/bgh175
  11. Motoyama N, Naka K (2004). DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev, 14, 11-6. https://doi.org/10.1016/j.gde.2003.12.003
  12. Olek A, Oswald J, Walter J (1996). A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res, 24, 5064-6. https://doi.org/10.1093/nar/24.24.5064
  13. Paige AJ (2003). Redefining tumour suppressor genes: exceptions to the two-hit hypothesis. Cell Mol Life Sci, 60, 2147-63. https://doi.org/10.1007/s00018-003-3027-6
  14. Permuth-Wey J, Sellers TA (2009). Epidemiology of ovarian cancer. Methods Mol Biol, 472, 413-37. https://doi.org/10.1007/978-1-60327-492-0_20
  15. Swisher EM, Gonzalez RM, Taniguchi T, et al (2009). Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer, 8, 48. https://doi.org/10.1186/1476-4598-8-48
  16. Varinderpal S (2004). Dhillon Mohd Shahid2 and Syed Akhtar Husain2 CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Molecular Cancer, 3, 33. https://doi.org/10.1186/1476-4598-3-33
  17. Widschwendter M, Berger J, Muller HM, Zeimet AG, Marth C (2001). Epigenetic downregulation of The retinoic acid receptor-beta2 gene in breast cancer. J Mammary Gland Biol Neoplasia, 6, 193-201. https://doi.org/10.1023/A:1011360724350

Cited by

  1. Aberrant Methylation of RASSF2A in Tumors and Plasma of Patients with Epithelial Ovarian Cancer vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1171
  2. Ascorbic acid improves pluripotency of human parthenogenetic embryonic stem cells through modifying imprinted gene expression in the Dlk1-Dio3 region vol.6, pp.1, 2015, https://doi.org/10.1186/s13287-015-0054-9
  3. Methylation Status and Expression of BRCA2 in Epithelial Ovarian Cancers in Indonesia vol.16, pp.18, 2016, https://doi.org/10.7314/APJCP.2015.16.18.8599
  4. Methylation status and protein expression of RASSF1A in endometriosis vol.11, pp.6, 2016, https://doi.org/10.3892/ol.2016.4512